STOCK TITAN
  1. Home
  2. News
  3. CINGW

Cingulate Inc - CINGW STOCK NEWS

Welcome to our dedicated news page for Cingulate (Ticker: CINGW), a resource for investors and traders seeking the latest updates and insights on Cingulate.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cingulate's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cingulate's position in the market.

News
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
Rhea-AI Summary
Cingulate Inc. to participate in Planet MicroCap Showcase: Vegas 2024, presenting its Precision Timed Release™ drug delivery platform technology. The company will host investor meetings and provide a webcast of the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.16%
Tags
conferences
-
News
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Rhea-AI Summary
Cingulate Inc. reports raising $17.8 million in 2023, with $9.1 million of debt converted to equity. The company's lead asset CTx-1301 shows promising Phase 3 ADHD data, attracting interest from pharmaceutical companies. Cingulate also received FDA guidance on its anxiety asset CTx-2103. The company raised $10.7 million and converted $3.3 million of debt to equity in 2024, with positive updates on financial and clinical fronts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
earnings
-
News
Cingulate to Participate in Benzinga All Live Access Event
Rhea-AI Summary
Cingulate Inc. announced CEO Shane J. Schaffer's participation in a Benzinga event to discuss their drug delivery platform technology, pipeline products, and recent updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Cingulate to Attend DCAT Week 2024 in New York City
Rhea-AI Summary
Cingulate Inc. to Host Licensing Meetings at DCAT Week 2024 with Global PharmaPartners, INC. to Discuss Pipeline and Technology, Featuring Lead Phase 3 Candidates for ADHD and Anxiety Treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
conferences
-
News
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
Rhea-AI Summary
Cingulate Inc. appoints three new directors to its board following successful capital raising activities, including a recent public offering and sales under its ATM facility. The company raised $7.5 million in February 2024, $3.2 million through the ATM facility in January 2024, and converted $3.3 million of debt into equity. The new directors bring expertise in business, public markets, finance, healthcare, and pharmaceuticals to support the company's clinical trials and business growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
management
-
News
Cingulate Announces Closing of $7.5 Million Public Offering
Rhea-AI Summary
Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) closed a public offering, raising $7.5 million in gross proceeds. The offering included 3,750,000 shares of common stock, Series A warrants, and Series B warrants. The company plans to utilize the net proceeds for research and development, commercialization activities, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.5%
Tags
offering
News
Cingulate Announces Pricing of $7.5 Million Public Offering
Rhea-AI Summary
Cingulate Inc. (CING) announced the pricing of its public offering of 3,750,000 shares of its common stock, Series A warrants for up to 3,750,000 shares, and Series B warrants for up to 1,875,000 shares at a public offering price of $2.00 per share. The offering is expected to raise significant capital for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.42%
Tags
offering
-
News
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
Rhea-AI Summary
Cingulate Inc. (NASDAQ: CING) has promoted Controller Jennifer Callahan to Chief Financial Officer, succeeding longtime CFO Lou Van Horn. The company aims to strengthen its balance sheet through traditional and non-dilutive transactions, with Callahan expressing excitement to lead the finance team into the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.59%
Tags
none
-
News
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
Rhea-AI Summary
Cingulate Inc. announced the conversion of $3.3 million of debt and accrued interest into equity by Werth Family Investment Associates, LLC, at a conversion price of $4.785 per share. The closing price of Cingulate’s common stock on Nasdaq on January 24, 2024, was $4.35 per share. WFIA also agreed to convert the remaining $3.0 million of principal under its outstanding note into pre-funded warrants to purchase 687,043 shares of Cingulate’s common stock. The offer and sale of the securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.59%
Tags
none
News
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
Rhea-AI Summary
Cingulate Inc. (NASDAQ: CING) has received guidance from the FDA to advance its investigational asset CTx-2103 for the treatment of anxiety into clinical development. The company plans to file an IND application in the first half of 2024 and design clinical studies for CTx-2103. This step may allow CTx-2103 to seek approval under the 505(b)(2) pathway, which typically requires less time and resources than the 505(b)(1) full NDA pathway. CTx-2103 is a once-daily, multi-dose tablet that provides three precisely timed doses of buspirone versus one immediate release dose, offering clear differentiation and compelling advantages over currently available treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
Stock CINGW logo
Cingulate Inc

Nasdaq:CINGW

CINGW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CINGW Stock Data

4.90M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Kansas City